Successful management of refractory hyperammonemia in metastatic neuroendocrine tumor
DOI:
https://doi.org/10.18203/2349-3933.ijam20161105Keywords:
Hyperammonemia, Neuroendocrine tumor, Hepatic encephalopathy, TACE, Liver tumorAbstract
Neuroendocrine tumors (NETs) form a heterogeneous group of neoplasms composed of pancreatic NETs and carcinoid tumors. Refractory hyper-ammonemia related encephalopathy is a condition seen rarely with metabolic liver disease and commonly with intra-abdominal shunts in the presence or absence of cirrhosis. We present here, a rare cause of medically refractory hyperammonemia, secondary to metastatic neuroendocrine tumor which was managed through interventional radiology measures. Apart from other causes of central nervous system involvement in metastatic neuroendocrine tumors, intratumoral microportovenous shunting and its management drastically improves outcomes and quality of life when diagnosed early.
References
Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6)707-12.
Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011;4(29).
Weng TI, Shih FF, Chen WJ. Unusual causes of hyperammonemia in the ED. Am J Emerg Med. 2004;22:105-7.
Nott L, Price T, Pittman K , Pattersona K , Fletcher J. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48:1702-11.
M. Mignon. Natural history of neuroendocrine enteropancreatic tumors. Digestion. 2000;62(1):51-8.
Reddy SK, Clary BM. Neuroendocrine liver metastases. Surg Clin North Am. 2010;90(4):853-61.
Vogl TJ, Naguib NNN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NEA. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009;72(3)517-28.
Clinicopathologic conference. Am J Med. 1991;90:374-80.
Erinjeri JP, Deodhar A, Thornton RH, Allen PJ, Getrajdman GI, Brown KT. Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol. 2009;31:299-307.
Turken O, Basekim C, Haholu A, Karagoz B, Bilgi O, Ozgun A, Kucukardali Y. Hyperammonemic encephalopathy in a patient with primary hepatic neuroendocrine carcinoma. Med Oncol. 2009;26:309-13.
Vandamme T, Kunnen J, Simoens M. Hyperammonemic encephalopathy in diffuse liver metastasis: is this the end stage? Gastroenterology. 2012;143(1):e9-e10.
Weng TI, Shih FF, Chen WJ. Unusual causes of hyperammonemia in the ED. Am J Med. 2004;22:105-7.
Mathias RS, Kostiner D, Packman S. Hyperammonemia in urea cycle disorders: role of the nephrologist. Am J Kidney Dis. 2001;37:1069-80.
Pavel ME, Baum U, Hahn EG, Hensen J. Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. International J Gastrointestinal Cancer. 2005;35:179-86.
